Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting

Table 6 Patient distribution as per MIDAS grades at each study time (47 patients)

		T0	T6		T12	T18
MIDAS grade I	n (%) 95% CI	0 (0.0) 0–100	17 (36.2) 25.2–48.9		16 (34.0) 23.3–46.7	26 (55.3) 42.8–67.2
MIDAS grade II	n (%) 95% CI	0 (0.0) 0–100	11 (23.4) 14.4–35.6		12 (25.5) 16.2–37.9	15 (31.9) 21.5–44.6
MIDAS grade III	n (%) 95% CI	14 (29.8) 18.3–44.5	12 (25.5) 15.0–40.1		16 (34.0) 21.8–48.8	5 (10.6) 4.4–23.4
MIDAS grade IV	n (%) 95% CI	33 (70.2) 55.5–81.7	7 (14.9) 7.2–28.4		3 (6.4) 2.0–18.3	1 (2.1) 0.3–14.1
p values from HGLM and pairwise comparisons
Outcome		Test for overall difference	T6 vs. T0	T12 vs. T6	T18 vs. T12	p for trend
MIDAS grade I		0.047	0.998	0.998	0.022	<0.001
MIDAS grade II		0.740	0.998	0.998	0.998	<0.001
MIDAS grade III		0.043	0.614	0.614	0.017	0.081
MIDAS grade IV		<0.001	<0.001	0.211	0.233	0.003